Prolongirovannaya kontratseptsiya medroksiprogesteronom u zhenshchin raznykh sotsial'nykh grupp: komplaentnost' i pobochnye reaktsii


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The article presents the results of a prospective cohort study involving 85 healthy women of different social groups aged 18-36 years; the study was aimed to the comparative evaluation of adherence to the prolonged contraception with medroxyprogesterone and frequency of side effects. Side effects associated with prolonged contraception with medroxyprogesterone occurred 1.8 times less, and adherence to treatment was up to 36 higher in women of low-income social group than among women of middle-income social class, that perhaps influenced by the lifestyle and standard of living, nutrition and physical activity of women.

Толық мәтін

Рұқсат жабық

Әдебиет тізімі

  1. Прилепская В.Н., Межевитинова Е.А., Назарова Н.М., Бостанджян Л.Л. Гормональная контрацепция / Под общ. ред. В.Н. Прилепской. М., 2011; 256.
  2. World Health Organization. Medical Eligibility Criteria for Contraceptive Use, 4th edition. Geneva: WHO, 2009. http://www.who.int/
  3. Медицинские критерии приемлемости методов контрацепции РФ. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 4-е издание, 2009». М., 2012; 242.
  4. Cardiovascular disease and use of oral and injectable progestogen-onlycontraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control-study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception. 1998; 57: 315-24.
  5. Дилигенский Г.Г. Люди среднего класса. М., 2002. 285 с.
  6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855691
  7. http://www.grandars.ru/college/sociologiya/socialnyy-status.html
  8. Bigrigg A., Evans M., Gbolade B., et al. DepoProvera. Position paper on clinica luse, effectiveness and side effects. Br. J. Fam. Plann. 1999; 25(2): 69-76.
  9. Draper B.H., Morroni C., Hoffman M., et al. Depotmedroxyprogesterone versus Norethisteroneoenanthate for long-acting progestogenic contraception. Cochrane Database of Systematic Reviews 2007; Issue 4: CD005214.
  10. Curtis K.M., Ravi A., Gaffield M.E. Progestogen-only contraceptive use in obese women. Contraception, 2009; 80: 346-354. World Health Organization. Cardiovascular disease and use of oral and injectable progestogen-only con traceptives and combined injectable contraceptives. Results of an international, multicenter, case-controlstudy. Contraception. 1998; 57: 315-24.
  11. Lopez L.M., Edelman A., Chen-Mok M., et al. Progestin-onlycontraceptives: effects on weight. Cochrane Database Syst. Rev. 2011; (4): CD008815.
  12. Clark M.K., Dillon J.S., Sowers M., et al. Weight, fatmass, and central distribution of fatincrease when women use depotmedroxyprogesteroneacetate for contraception. International J. Obesity, 2005; 29: 1252-58.
  13. Clark M.K., Stockdale C.K., Railsback L., et al. Differences in cervical cytologic and histologic findings between women using depot-medroxyprogesteroneacetate and oral contraceptives. J. Low Genit. Tract Dis. 2011; 15(3): 219-23.
  14. Kaunitz A.M. Injectable contraception. New andexisting options. Obstet. Gynecol. Clin. North Am. 2000; 27(4): 741-80.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2014

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>